This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cytokinetics. Cytokinetics ...

Investing.com -- Shares of Cytokinetics (NASDAQ: CYTK ), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (NASDAQ: SNY) will acquire exclusive rights to develop and ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...

Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel ...

Cytokinetics, Inc.(CYTK), a late-stage, specialty cardiovascular biopharmaceutical company, Friday announced that French drug major ...

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Sanofi will acquire ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten ...

Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 ...

Sanofi has announced plans to invest approximately €1bn to build a new insulin production base in China. The site, located in the Beijing Economic and Technological Development Zone, will be aimed at ...

(RTTNews) - French drug major Sanofi plans to invest around 1 billion euros or about $1.05 billion to build a new insulin manufacturing base in Beijing, China, reports said. The move represents ...

Sanofi SA will invest around 1 billion euros ($1.1 billion) to build a new insulin production base in Beijing, its biggest single investment in China to date and part of a broader push to boost ...